Skip to main content
. 2022 Jan 31;28(4):214.e1–214.e11. doi: 10.1016/j.jtct.2022.01.019

Figure 1.

Figure 1

Flow chart of the study. A total of 110 allo-HCT recipients and 86 healthy controls were enrolled. Results are available for 101 patients and 74 healthy controls at T1 (14 to 35 days post-first dose), for 101 patients and 72 controls at T2 (14 to 42 days post-second dose), for 96 patients and 70 controls at T3 (65 to 115 days post-second dose), and for 68 patients and 48 controls at T4 (135 to 225 days post-second dose).